PARTNERSHIP OPPORTUNITIES
With investment insecurity at the forefront of iPSC leaders’ minds, it has never been more prevalent to establish reliable, collaborative and long-term partnerships with gold standard service providers. As the largest meeting dedicated solely to iPSC-derived drug development, the 3rd Annual iPSC-Derived Cell Therapies Summit provided the perfect opportunity to network with the top companies pioneering iPSC-based drug development in an intimate and focussed forum.
Experts had showcased their expertise in genetic engineering, scale-up capacities, cell-banking, and refined differentiation technologies to decision makers, actively looking for these solutions. Don’t miss out on the exclusive opportunity to align with iPSC leaders and accelerate iPSC-derived cell therapies to the clinic next year.
Our 2024 Partners
Experts Need Your Help With:
- Establishing genomic integrity and maintaining safety during gene editing processes
- Developing reliable pre-clinical models to confidently recapitulate disease indications to ensure more robust preclinical data
- Meaningful product characterization through high quality analytical tests for potency, efficacy and toxicology
- Providing safe and reproducible starting materials and cell-lines to form a top-quality master cell bank
- Maintaining efficacy and regulatory compliance through scale-up across the pre-clinical pipeline
Why Partner?
Demonstrate the value of your services to decision makers actively looking for long-term, collaborative partnerships to support the advancement of iPSC-derived therapies to the clinic
Understand the biggest challenges being faced by iPSC drug developers from the 30+ expert speakers to identify market gaps and inform your commercial strategy for 2023 and beyond
Who Will Did You Meet in 2023?
Luke Kindness
Business Development Manager
Hanson Wade
sponsor@hansonwade.com